
Opinion|Videos|February 28, 2025
CheckMate-9ER: Updates Presented at ASCO 2025
Panelists discuss how the latest progression-free survival, overall survival, and overall response rate data presented at ASCO 2025 demonstrate significant advancements in treatment efficacy across multiple tumor types.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















